An FDA advisory panel voted this week to add six peptides to the drug compounding list, including compounds like kisspeptin-10 and TB-500. The panel rejected emideltide. Shares of HIMS climbed overnight following the committee's endorsement of four peptides. Bachem shares held steady after the vote. A recent study indicated peptides may aid treatment of antibiotic-resistant bacteria. Meanwhile, Robert F. Kennedy Jr. pushed for broader availability to controversial peptides, calling for slackened rules. The vote reflects a broader shift in how regulators view custom-mixed peptide therapies, which have drawn growing interest from users seeking alternatives to traditional drugs. Researchers say peptide treatments could reshape approaches to resistant infections, though concerns about consistency persist. The committee's endorsement of four peptides opens the door for more widespread prescribing, even as critics warn of long-term evidence. Sector observers note that peptide-focused companies may see increased investor attention following the panel's decision. The rejection of emideltide, meanwhile, underscores the FDA's cautious stance on certain peptide candidates.